Advancing the
diagnosis.
Testing for the full spectrum of hematologic disorders.
Our comprehensive test menu has been
created to aid in diagnosis and treatment
selection across the full spectrum of hematologic
disorders. Through our clinical experience, we
have developed and validated practice-based,
data-driven algorithms that improve patient care, increase efficiency, and reduce costs.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly hematology testing newsletter.
Results That Matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
1 million
hematology and hematopathology tests performed annually
70+
hematologists and hematopathologists on staff at Mayo Clinic
23
hematology-focused algorithms to guide test ordering
24/7
support from Mayo Clinic physicians and scientists
Innovation and collaboration between experts
Our laboratories are led by board-certified hematopathologists who focus on molecular diagnostics and prognostics of hematologic disorders, reviewing cases to provide interpretation of results related to clinically relevant genes. These experts are on call 24/7, so they are available any time you need answers.
The right test
at the right time
More than 20 hematology-focused algorithms are integrated directly into our testing approaches to ensure the right tests are being ordered at the right time. This approach simplifies the ordering process, arriving at clinically actionable answers for your patients, faster.
Unparalleled service
Our testing is supported by a round-the-clock staff of expert laboratory directors and genetic counselors, who assist with everything from test ordering to results interpretation. Our experts collaborate closely with clients, not only to reach the right answers for current patients, but also to guide the development of future testing.
A Case-Based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis
Using test-ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and the literature, we will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.
The Latest
In this month's "Hot Topic," Dragan Jevremovic, M.D., Ph.D., reviews the current state of testing for diagnosis, therapy, and stratification of patients with multiple myeloma.
The results are part of a comprehensive study of 16,175 cases performed at Mayo Clinic over an 11-year period.
Horatiu Olteanu, M.D., Ph.D., gives an overview of the new T-cell receptor (TCR) β-chain constant region (TRBC1) flow cytometry marker, which is now included in Mayo Clinic Laboratories' routine diagnostic T-cell flow cytometry panel. He discusses when this testing should be ordered, how the addition of TCRBC1 compares to previous testing approaches, and how this marker can assist ordering physicians.
Rajiv Pruthi, M.B.B.S., gives an overview of this testing available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.
Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.